I recruit biotech executive and clinical/regulatory leadership in Boston-Cambridge — the top U.S. market for life sciences R&D talent, where near-zero Kendall Square lab vacancy coexists with layoffs at Takeda, Sarepta, and Moderna. Contingent-first, no up-front retainer, twelve-month guarantee.

Biotech Recruiters in Boston

Boston-Cambridge is the top U.S. market for life sciences R&D talent, according to CBRE’s 2025 Life Sciences Talent Trends report — leading the nation in bioengineers, biomedical engineers, biochemists, biophysicists, and medical scientists, and it surpassed New York-New Jersey as the top region for life sciences manufacturing talent in 2025. Kendall Square in Cambridge, next to MIT, is the historic heart of the cluster, hosting more than 600 life sciences companies in a single square mile, with Class A lab vacancy near zero for more than a year as of early 2026.

That strength sits alongside real softness. Massachusetts recorded 143,224 life sciences jobs in 2025, essentially flat against 144,669 in 2024 — the state’s first employment decline in over a decade after 14 consecutive years of growth. Major layoffs have hit the market directly: Takeda cut 247 Kendall Square jobs starting July 2026 as part of a larger restructuring (even while leaving roughly 700 open positions company-wide), alongside a 36% workforce cut at Sarepta Therapeutics, a 10% cut at Moderna, and nearly 300 jobs cut at Thermo Fisher across Cambridge and Plainville. Despite that, Massachusetts still pulled in $6.85 billion in venture capital across 197 rounds in 2025, and life sciences unemployment in the state has stayed below 2.0% — this is a bifurcated market, not a uniformly contracting one.

Where this fits in Boston

Executive searches at platforms managing the bifurcation directly — CEO, CSO, and CMO roles where a board needs someone who can navigate near-zero core lab availability and investor expectations while peer companies are cutting headcount.

Cell and gene therapy manufacturing leadership, where demand outpaces supply by roughly 3 to 1 — one of the most acute technical shortages in any U.S. biotech market.

CMC regulatory affairs and VP of Regulatory Affairs searches, a second acute shortage area distinct from general regulatory-compliance hiring, plus AI/ML drug discovery leadership sourced increasingly from Big Tech and quantitative finance rather than traditional biotech backgrounds.

Every search starts with mapping the platform’s position in this bifurcated market — a Kendall Square tenant facing near-zero lab vacancy has a different hiring urgency than a secondary-submarket platform competing in a market with record vacancy. From there, outreach targets the specific development-stage and therapeutic-area experience the mandate calls for, informed by the concentration of comparable platforms and investor relationships unique to this cluster. Every placement carries the standard twelve-month guarantee.

Hub home: Biotech Recruiters. Cross-vertical: executive search agency.

Schedule a 30-Minute Call with Dan — Calendly, dpoore@bluesignal.com, or 669-900-4504. That is the only conversion path.

Frequently asked questions

Is Boston still the top biotech talent market despite the layoffs?

Yes. CBRE's 2025 Life Sciences Talent Trends report named Boston-Cambridge the top U.S. market for life sciences R&D talent, leading the nation in bioengineers, biochemists, biophysicists, and medical scientists, and it also surpassed New York-New Jersey as the top region for life sciences manufacturing talent in 2025.

What makes Kendall Square distinct within the Boston market?

Kendall Square in Cambridge, next to MIT, hosts over 600 life sciences companies within a single square mile, and Class A lab vacancy there has stayed near zero for more than a year as of early 2026 — even as broader Boston-metro lab vacancy hit a record 28% by Q4 2025 in secondary submarkets.

Which skills are hardest to source in Boston right now?

Cell and gene therapy manufacturing, where demand outpaces supply by roughly 3 to 1, AI/ML drug discovery talent (drawn mostly from Big Tech and quant finance), and CMC regulatory affairs are the three acute shortage areas, even with major 2025-2026 layoffs at Takeda, Sarepta, and Moderna.

What's the engagement model for a Boston biotech search?

Contingent-first, no up-front retainer, twelve-month replacement guarantee — the same terms as every other search this desk runs nationally.